The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
The NDA is supported by data from a clinical trial that compared the absorption and efficacy of the nasal treatment with oral and IV bumetanide in 68 healthy adults.
Hosted on MSN24y
Common Types of Nasal Sprays — and How to Use ThemMedically reviewed by John Carew, MD Fact checked by Jillian Dara Nasal sprays can treat congestion and other symptoms of ...
In our experience, Flonase Allergy Relief Nasal Spray is a highly effective allergy medication that delivers prescription-strength non-drowsy relief all day and night. We found that the nasal ...
"We are pleased the FDA has accepted our NDA for Bumetanide Nasal Spray," said Benjamin Esque, CEO of Corstasis Therapeutics ...
A new "powerful tool" for combatting opioid deaths isn't settled science. For that reason, the state is taking a measured ...
HealthDay on MSN6d
FDA Approves Spravato Nasal Spray for Treatment-Resistant DepressionThe U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with ma ...
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
The spray, called Spravato, is now the first-ever standalone therapy for treatment-resistant depression, which is when trying at least two standard treatments does little to nothing to improve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback